Quick Answer
TG THERAPEUTICS, INC. reported Research And Development Expense of $160.22 million for the year ending 2025.
- TG THERAPEUTICS, INC. showed an increase of +69.9% in Research And Development Expense from 2024 to 2025.
- This data is from TG THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), TG THERAPEUTICS, INC.'s Research And Development Expense has grown by 48,853.0%.
- Historical annual values: Fiscal year 2025: $160.22 million | Fiscal year 2024: $94.29 million | Fiscal year 2023: $76.19 million | Fiscal year 2022: $125.35 million | Fiscal year 2021: $222.58 million | Fiscal year 2020: $165.90 million | Fiscal year 2019: $154.18 million | Fiscal year 2018: $159.39 million | Fiscal year 2017: $102.53 million | Fiscal year 2016: $69.23 million | Fiscal year 2015: $47.71 million | Fiscal year 2014: $40.09 million | Fiscal year 2013: $13.66 million | Fiscal year 2012: $21.03 million | Fiscal year 2011: $327.3 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: